Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10197981 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kretzschmar M, Doody J, Timokhina I, Massagué J (1999) A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 13, 804-16 10197981
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T220-p - Smad2 (human) ▲
Orthologous residues
Smad2 (human): T220‑p, Smad2 (mouse): T220‑p, Smad2 (rat): T220‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization

S245-p - Smad2 (human) ▲
Orthologous residues
Smad2 (human): S245‑p, Smad2 (mouse): S245‑p, Smad2 (rat): S245‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization

S250-p - Smad2 (human) ▲
Orthologous residues
Smad2 (human): S250‑p, Smad2 (mouse): S250‑p, Smad2 (rat): S250‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization

S255-p - Smad2 (human) ▲
Orthologous residues
Smad2 (human): S255‑p, Smad2 (mouse): S255‑p, Smad2 (rat): S255‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization

T179-p - Smad3 (human) ▲
Orthologous residues
Smad3 (human): T179‑p, Smad3 (mouse): T179‑p, Smad3 (rat): T179‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, transcription, altered

S204-p - Smad3 (human) ▲
Orthologous residues
Smad3 (human): S204‑p, Smad3 (mouse): S204‑p, Smad3 (rat): S204‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, transcription, altered

S208-p - Smad3 (human) ▲
Orthologous residues
Smad3 (human): S208‑p, Smad3 (mouse): S208‑p, Smad3 (rat): S208‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, transcription, altered

S213-p - Smad3 (human) ▲
Orthologous residues
Smad3 (human): S213‑p, Smad3 (mouse): S213‑p, Smad3 (rat): S213‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  EpH4 (epithelial), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  mink, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase activated (V12)
PD98059 HRas (human) inhibit treatment-induced increase activated (V12)
wortmannin HRas (human) inhibit treatment-induced increase activated (V12)
MEK1 (human) increase constitutively active
EGF increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.